FORM 10-Q

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

         [ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                        SECURITIES EXCHANGE ACT OF 1934
                  For the quarterly period ended June 30, 1998

                                       OR

              [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934
       For the transition period from .................to.................

                         Commission file number 33-19583

                            ZEVEX INTERNATIONAL, INC.
               (Exact name of registrant as specified in charter)

          DELAWARE                           87-0462807 
(State or other jurisdiction of         (I.R.S.  Employer  
incorporationor organization)            Identification No.)

                4314 ZEVEX Park Lane, Salt Lake City, Utah 84123
              (Address of principal executive offices and zip code)

                                 (801) 264-1001
              (Registrant's telephone number, including area code)

                                 NOT APPLICABLE
(Former name,former address,and former fiscal year,if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days. Yes [ X ] No

                APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Indicate  by check mark  whether  the  registrant  has filed all  documents  and
reports  required  to be filed by  Sections  12,  13 or 15(d) of the  Securities
Exchange Act of 1934 subsequent to the  distribution of securities  under a plan
confirmed by a court.
Yes  [   ]    No  [   ]    Not Applicable  [ X ]
                      APPLICABLE ONLY TO CORPORATE ISSUERS
Indicate the number of shares  outstanding  of each of the  issuer's  classes of
common  stock,  as of the latest  practicable  date.  As of July 15,  1998,  the
Company had outstanding  3,300,176  shares of common stock, par value $0.001 per
share.

                   Page 1 of 10 consecutively numbered pages

<PAGE>







                                     PART I

                              FINANCIAL INFORMATION

-------------------------------------------------------------------------------

               ITEM 1. FINANCIAL STATEMENTS REQUIRED BY FORM 10-Q
-------------------------------------------------------------------------------

ZEVEX International,  Inc. (the "Company"), files herewith balance sheets of the
Company as of June 30, 1998, and December 31, 1997,  and the related  statements
of  operations  and cash  flows  for the  respective  three  month and six month
periods  ended  June  30,  1998,  and  1997.  In the  opinion  of the  Company's
management,  the financial statements reflect all adjustments,  all of which are
normal  recurring  adjustments,   necessary  to  fairly  present  the  financial
condition  of the Company  for the  interim  periods  presented.  The  financial
statements  included in this  report on Form 10-Q should be read in  conjunction
with the audited  financial  statements  of the  Company  and the notes  thereto
included  in the  annual  report of the  Company on Form 10-K for the year ended
December 31, 1997.

                            See accompanying notes.
<PAGE>





                                                  

                            ZEVEX INTERNATIONAL, INC.
                           CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>


                                                          ASSETS
                                                                           June 30                        Dec. 31

                                                                            1998                           1997
                                                                            -----                          ----
                                                                         (unaudited)
Current assets:
            <S>                                                         <C>                               <C>
             Cash and cash equivalents                                   $     387,446                     $2,260,426
             Restricted cash for sinking
                fund payment on industrial
                 development bond                                              128,425                         76,164
             Accounts receivable                                             2,638,762                      2,095,455
             Inventories                                                     3,886,277                      3,540,591
             Marketable securities                                          10,741,463                     10,403,109
             Deferred income taxes                                              82,930                         82,930
             Prepaid expenses                                                   49,955                         67,307
                                                                        ---------------                ---------------
                              Total current assets                          17,915,258                     18,525,982

             Property and equipment, net                                     4,639,369                      3,933,804
             Patents and trademarks                                            134,686                        122,002
             Other assets                                                          755                            755
                                                                                   ---                            ---
                                                                        $   22,690,068                 $   22,582,543
                                                                        ==============                 ==============

                                         LIABILITIES & STOCKHOLDERS' EQUITY
Current liabilities:
             Accounts payable                                               $  570,721                       $640,579          
             Other accrued expenses                                            261,619                        264,484
             Income taxes payable                                               15,539                        285,403
             Current portion of industrial development bond                    100,000                        100,000
                                                                        ---------------                 --------------
                              Total current liabilities                        947,879                      1,290,466

              Deferred income taxes                                            146,583                        126,380
              Industrial development bond                                    1,800,000                      1,900,000

Stockholders' equity:
             Common stock, $.001 par value: authorized 10,000,000
                shares, issued 3,298,176 and 3,264,326
                 shares, respectively                                            3,298                          3,265
              Additional paid in capital                                    16,815,580                     16,697,203
             Less: Treasury stock                                             (50,790)                             --
             Retained earnings                                               3,027,518                      2,565,229
                                                                             ---------                      ---------
                   Total stockholders' equity                               19,795,606                     19,265,697
                                                                            ----------                     ----------
                                                                        $   22,690,068                 $   22,582,543
                                                                        ==============                 ==============

</TABLE>

                            See accompanying notes.

<PAGE>







                                                  

                            ZEVEX INTERNATIONAL, INC.
                            STATEMENTS OF OPERATIONS

<TABLE>
<CAPTION>

                                                Three months ended                                   Six months ended
                                                     June 30,                                            June 30,





                                            1998                  1997                      1998                      1997
                                     -------------------     ----------------        -------------------       --------------------
                                        (unaudited)            (unaudited)               (unaudited)                (unaudited)
Revenue:
  <S>                              <C>                    <C>                       <C>                         <C>             
   Product sales                    $       2,765,873      $       1,551,060         $      4,904,424            $      3,139,186
   Engineering services                       333,480                 52,200                  382,640                     675,179
                                    ------------------     ------------------       ------------------        --------------------
                                            3,099,353              1,603,260                5,287,064                   3,814,365
Cost of sales                               1,582,604                768,114                2,860,027                   1,940,789
                                    ------------------     ------------------       ------------------        --------------------
Gross profit                                1,516,749                835,146                2,427,037                   1,873,576

Operating expenses:
  General and administrative                  750,695                338,985                 1,283,022                    725,394
  Selling and marketing                       294,472                175,065                   592,689                    333,457
  Research and development                     51,890                272,494                   155,974                    458,121
                                     -----------------     ------------------       -------------------       --------------------

Total operating expenses                    1,097,057                786,544                2,031,685                   1,516,972

Operating income                              419,692                 48,602                  395,352                     356,604
Other income (expense):
   Interest income                            155,850                 24,758                  269,065                      61,835
   Interest expense                          (27,646)               (20,641)                 (44,414)                    (37,463)
   Unrealized gain on                                                                                                          
     marketable securities                     11,718                      -                   74,214                           -
                                    ------------------     ------------------       ------------------        --------------------
Income before provision for                                                                                        
   income taxes                               559,614                 52,719                  694,217                     380,976

Provision for taxes                         (212,333)                  4,268                (231,928)                    (98,451)
                                    ------------------     ------------------       ------------------        --------------------

Net income                          $          347,281     $          56,987        $         462,289         $            282,525
                                    ==================     ==================       ==================        ====================

Basic net income per share         $               .11     $              .03       $             .14         $                .15
                                                                                                          
                                    ==================     ==================       ==================        ====================
Weighted average shares                                           
   outstanding                              3,297,688               1,995,716                3,289,312                   1,876,932
                                    ==================     ==================       ==================        ====================

Diluted net income per share                       .10                    .02                     .13                          .12
                                                                                             
                                    ==================     ==================       ==================        ====================
Diluted weighted average shares                                                                             
   Outstanding                              3,654,132               2,445,541                3,652,666                   2,363,694
                                    ==================     ==================       ==================        ====================

</TABLE>
                            See accompanying notes.


<PAGE>











                            ZEVEX INTERNATIONAL, INC.
                      CONSOLIDATED STATEMENTS OF CASH FLOWS

<TABLE>
<CAPTION>


                                                                            Six months ended
                                                                                June 30,
                                                                       1998               1997
                                                                  ---------------    ---------------
                                                                    (unaudited)        (unaudited)
Cash flows from operating activities 
<S>                                                              <C>                <C>           
Net income                                                        $      462,289     $      282,525

Adjustments to reconcile  net income to net cash (used in) provided by operating
   activities:
      Depreciation and amortization                                      220,386            164,418
      Benefit for deferred income taxes                                   20,203                 --
      Unrealized gain on marketable securities                          (74,214)                 --
      Changes in operating assets and liabilities:
         Increase in restricted cash for sinking fund payment           
            on industrial development bond                              (52,261)                 --
         (Increase) decrease in accounts receivable                    (543,307)            599,476
         Increase in inventories                                       (345,686)        (1,084,804)
         Increase in marketable securities                             (264,140)                 --
         Decrease (increase) in prepaid expenses                          17,352            (2,242)
         Decrease in taxes receivable                                         --             41,458
         (Decrease) increase in accounts payable                        (69,858)            125,594
         Decrease in accrued liabilities                                 (2,865)           (54,916)
        (Decrease) increase in income taxes payable                    (269,864)             46,883
                                                                  ---------------    ---------------
Net cash (used in) provided by operating activities                    (901,965)            118,392
Cash flows from investing activities
Purchase of property and equipment                                     (925,951)        (2,591,116)
Additions to patents and trademarks                                     (12,684)                 --
                                                                  ---------------    ---------------
Net cash used in investing activities                                  (938,635)        (2,591,116)
Cash flows from financing activities
Proceeds from issuance of common stock                                        --          1,250,000
Proceeds from exercise of stock options                                   13,410                 --
Proceeds from exercise of warrants                                       105,000                 --
Purchase of treasury stock                                              (50,790)                 --
Repayment of bank line of credit                                              --           (60,108)
Repayment of industrial development bond                               (100,000)
                                                                  ---------------    ---------------
Net cash (used in) provided by financing activities                     (32,380)          1,189,892
                                                                  ---------------    ---------------
Net decrease in cash and cash equivalents                            (1,872,980)        (1,282,832)
Cash and cash equivalents at beginning of period                       2,260,426          2,085,055
                                                                  ---------------    ---------------
Cash and cash equivalents at end of period                           $   387,446        $   802,223
                                                                  ===============    ===============
</TABLE>

                            See accompanying notes.



<PAGE>





                            ZEVEX INTERNATIONAL, INC.

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

                                  June 30, 1998


1.  Summary of Significant Accounting Policies

The Company was  incorporated  under the laws of the State of Nevada on December
30, 1987. The Company was originally  incorporated as Downey  Industries,  Inc.,
and  changed  its name to ZEVEX  International,  Inc.,  on August 15,  1988.  In
November 1997, the Company reincorporated into Delaware. The Company designs and
manufactures  advanced  medical  devices,  including  surgical  systems,  device
components,  and sensors  for medical  technology  companies.  The Company  also
designs, manufactures, and markets its own medical devices using its proprietary
technologies.  The  Company's  design and  manufacturing  service  customers are
medical technology  companies,  who sell the Company's systems and devices under
private labels or incorporate the Company's devices into their products.

The  accompanying  financial  statements  have been prepared in accordance  with
generally accepted accounting  principles for interim financial  information and
with the  instructions  to Form 10-Q of  Regulation  S-X.  Accordingly,  certain
information and footnote  disclosures  normally  included in complete  financial
statements have been condensed or omitted.  These financial statements should be
read in conjunction with the financial statements and footnotes thereto included
in the Company's 1997 Annual Report and Form 10-K.

In the  opinion  of  management,  all  adjustments  (consisting  of  normal  and
recurring  adjustments)  considered  necessary for a fair presentation have been
included.  The results of operations  for interim  periods are not indicative of
the results of operations to be expected for a full year.

2. Inventories

Inventories consist of the following:
<TABLE>
<CAPTION>


                                                               June 30            December 31
                                                                 1998                   1997
                                                        ------------------    -----------------
                              <S>                     <C>                    <C>               
                               Materials               $         2,358,521   $        2,306,818
                               Work in progress                  1,363,494            1,044,331
                               Finished Goods,
                                 including completed
                                 subassemblies                     164,262              189,442
                                                       -------------------    -----------------
                                                       $         3,886,277   $        3,540,591
                                                       ===================    =================
</TABLE>


3.  Bank Line of Credit

On December 31, 1997, the Company renewed its line of credit  arrangement with a
financial  institution for $5 million.  The line matures on August 30, 1998. The
line of credit is collateralized by accounts  receivable and inventory and bears
interest at the prime rate (8.5% at June 30, 1998,  and at December  31,  1997).
The  Company's  balance  on its line of  credit  was  zero at June 30,  1998 and
December 31, 1997. Under the line of credit agreement, the Company is restricted
from  declaring  cash  dividends.  The renewal of the  Company's  line of credit
resulted in the addition of certain  financial  covenants.  As of June 30, 1998,
the Company was in compliance with these financial covenants.

4.  Stockholders' Equity

Repurchase of Common Stock

On February 4, 1998, the Company  repurchased 6,700 shares of outstanding Common
Stock  for  $50,790.  The  Company  anticipates  that  all  the  shares  will be
contributed to the Employees' Stock Ownership Plan.

5.  Related Party Transactions

On April 15, 1997, the Company entered into a consulting  agreement with another
company owned by certain  stockholders to provide  services related to strategic
planning, public relations,  financing and potential acquisition of new products
or companies. Under the consulting agreement, the Company paid an initial fee of
$50,000, and must pay $10,000 per month for two years.

In connection  with the secondary  public  offering  completed in November 1997,
certain  stockholders waived their registration  rights on 350,000 warrants.  In
exchange,  the  Company  and the  stockholders  executed a  registration  rights
agreement,  entitling the stockholders to certain demand registration rights for
a period of two years from February 1, 1998.

6.    Comprehensive Income

Effective January 1, 1998, the Company adopted Statement of Financial Accounting
Standards No. 130, "Reporting  Comprehensive  Income" ("SFAS 130"). SFAS No. 130
requires that all items recognized  under accounting  standards as components of
comprehensive  income be  reported  in an  annual  financial  statement  that is
displayed with the same prominence as other annual  financial  statements.  This
statement  also requires that an entity  classify  items of other  comprehensive
income by their nature in an annual  financial  statement.  Other  comprehensive
income may include  foreign  currency  translation  adjustments,  and unrealized
gains and losses on marketable securities classified as available-for-sale.  For
the first six months  ending  June 30,  1998,  SFAS No. 130 had no effect on the
Company's financial statements.


<PAGE>


------------------------------------------------------------------------------

                 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF
                  FINANCIAL CONDITION AND RESULTS OF OPERATIONS
-------------------------------------------------------------------------------

Results of Operations

The Company's  revenues for the second  quarter of 1998 increased to $3,099,353,
from $1,603,260 for the second quarter of 1997, an increase of approximately 93%
for the three  months  ended  June 30,  1998.  For the first six months of 1998,
revenues  increased 39% to $5,287,064  from  $3,814,365 for the six months ended
1997.  During the first six months of 1998, 57% of total  revenues,  compared to
68% of total  revenues for the first six months of 1997,  resulted from sales to
three  customers,  all of whom  were  major  customers  in  1997.  Sales  of the
Company's  Proprietary  Product,  the EnteraLite(R)  Ambulatory  Enteral Feeding
Pump,  accounted  for  approximately  15% of the total  revenues  for the second
quarter of 1998, compared to 14% for the second quarter of 1997. The majority of
the  Company's  products are  manufactured  for and sold to OEM  customers,  who
market the final  product.  The Company's  manufacturing  revenue growth depends
upon growth in demand for  systems,  devices  and  instruments  manufactured  by
ZEVEX, and ZEVEX's ability to acquire additional manufacturing service contracts
from medical technology companies. ZEVEX's contract manufacturing customers have
complete   control  over  the   marketing  and  sales  of  products  that  ZEVEX
manufactures  for them.  ZEVEX has no ability to increase demand for instruments
that it manufactures for its contract-manufacturing customers. No assurances can
be given that orders from any customer will increase or remain at current levels
or that they will not decline.

The Company's gross profit as a percentage of revenues was approximately 49% for
the three months ended June 30, 1998, as compared to 52% for 1997. Gross profits
for six  months  ended  June 30,  1998,  were  46% for  1998  and 49% for  1997.
Management attributes the decrease mainly to an increase in expenses relating to
the Company's proprietary product, the EnteraLite(R)  Ambulatory Enteral Feeding
Pump. The rapid increase in sales of the EnteraLite(R) Feeding Pump exceeded the
current  production  capacity of ZEVEX's  outside  supplier of disposable  sets.
Consequently,  the Company  experienced  a surge in the cost of sales related to
this  product,  due to  increased  shipping  and related  expenses  necessary to
maintain our obligation to our customers and our reputation for service.

Selling, general and administrative expenses for the three months ended June 30,
1998,  increased $531,117,  from $514,050 in 1997 to $1,045,167 in 1998. For six
months  ended June 30,  1998,  selling,  general  and  administrative  increased
$816,860  from  $1,058,851 in 1997 to  $1,875,711  in 1998.  Increased  expenses
resulted  from the  Company's  continuing  growth.  The  Company  had  increased
expenses related to its listing on the American Stock Exchange, increased legal,
accounting,  general consulting and Public and Investor  Relations.  An expanded
sales  and  marketing  effort  increased  staffing,   travel,   advertising  and
administrative  expenses related to the EnteraLite(R)  Feeding Pump. The Company
also had an increase in expenses related to employees, such as insurance, taxes,
and pension  benefits.  The Company  believes  that  general and  administrative
expenses  in 1998 as related to sales will  continue at  approximately  the same
percentage as in the previous two years.

Research and development  expenses vary from quarter to quarter depending on the
number and nature of pending research and development projects and their various
stages of  completion.  For the three months  ended June 30, 1998,  research and
development expenses were $51,890 in 1998, compared to $272,494 in 1997. For six
months ended June 30, 1998, research and development  expenses were $155,974 for
1998 and $458,121 for 1997. Significant fluctuations experienced in research and
development are due to the timing of the Company's research  projects.  Expenses
incurred  during the second  quarter were for the continued  development  of new
applications of the Company's  ultrasound  technology and proprietary  products.
Management  believes  investing  in  research  and  development  will  serve the
Company's  future  well,  and  intends  to  continue  this  investment  for  the
foreseeable  future.   Research  and  development   expenses  will  continue  at
approximately the same percentage as in the previous two years.

Net income increased to $347,281, approximately 11.2% of revenues, for the three
months ended June 30, 1998,  from $56,987,  approximately  3.6% of revenues,  in
1997. Net income for six months ended June 30, 1998, increased to $462,289, 8.7%
of revenues,  from $282,525,  7.4% of 1997 revenues.  The increase in net income
during the second quarter of 1998, as compared to the second quarter of 1997, is
principally due to increased revenues generated by the Company.

As of June 30, 1998, the Company's backlog of customer orders was $5,695,807, as
compared to $7,739,000 on June 30, 1997. Management estimates that approximately
90% of the backlog will ship before December 31, 1998.


Liquidity and Capital Resources

During the three months and six months ended June 30, 1998, the Company produced
$347,281  and $462,289 in net income  respectively  from  operating  activities,
compared  to net incomes of $56,987 and  $282,525,  respectively,  for the three
months and six months ended June 30, 1997.  Cash decreased by $1,872,980 for the
six months ending June 30, 1998, as the Company continued to fund an increase in
accounts  receivable and inventories,  as well as purchases related to property,
plant and equipment.

The  Company's  investment in property,  patents from new research,  production,
test  equipment and tooling was $938,635 for the six months ended June 30, 1998,
compared to $1,218,830 in 1997. The Company paid $580,000 in the exercise of its
first right of refusal to purchase a parcel of land,  approximately  3.47 acres,
to the north of its facility.  Total expenditures for equipment of $358,635 were
primarily  due to  upgrading  the  Company's  research,  design and  engineering
capabilities.  The  Company  expects  to spend  approximately  $150,000  for the
remainder of 1998 for additional  manufacturing equipment, as well as for normal
replacement  of  old  equipment.  The  Company  also  anticipates  approximately
$550,000 of additional research and development expenses during 1998.

The  Company's  working  capital at June 30, 1998 was  $16,967,379,  compared to
$3,529,342 at June 30, 1997. The increase in working capital is primarily due to
the secondary  offering that was completed in November 1997, as described in the
Stockholders'  Equity section of the Notes to Consolidated  Financial Statements
in the Company's 1997 Annual Report. The portion of working capital  represented
by cash at such dates was $387,446 and  $802,223  respectively.  The Company has
$10,352,999 in short term,  investment  grade,  interest bearing  investments at
June 30, 1998.  The Company uses  substantial  portions of its cash from time to
time to fund  its  operations,  including  increases  in  inventories,  accounts
receivable and work in process in connection with various customer orders.



<PAGE>


Cautionary Statement for Purposes of "Safe Harbor Provisions" of the Private
Securities Litigation Reform Act of 1995

When used in this report, the words "estimate," "believe," "project" and similar
expressions,  together with other  discussion  of future trends or results,  are
intended to identify  forward-looking  statements  within the meaning of Section
27A of the Securities Act of 1933, as amended (the "Securities Act") and Section
21E of the  Securities  Exchange Act of 1934, as amended (the  "Exchange  Act").
Such statements are subject to certain risks and uncertainties,  including those
discussed below, that could cause actual results to differ materially from those
projected.  These  forward-looking  statements speak only as of the date hereof.
All of these  forward-looking  statements are based on estimates and assumptions
made by management of the Company, which although believed to be reasonable, are
inherently uncertain and difficult to predict.  Therefore, undue reliance should
not be placed upon such  estimates.  There can be no assurance that the benefits
anticipated in these forward-looking  statements will be achieved. The following
important  factors,  among  others,  could  cause the Company not to achieve the
benefits  contemplated  herein,  or  otherwise  cause the  Company's  results of
operations  to be  adversely  affected  in  future  periods:  (i)  continued  or
increased competitive pressures from existing competitors and new entrants; (ii)
unanticipated  costs related to the Company's  growth and operating  strategies;
(iii) loss or retirement of key members of management; (iv) increase in interest
rates of the Company's  cost of borrowing,  or a default under any material debt
agreement;  (vi) prolonged labor disruption;  (viii) deterioration in general of
regional  economic  conditions;  (ix) adverse  state or federal  legislation  or
regulation  that  increases  the cost of  compliance,  or adverse  findings by a
regulator  with  respect  to  existing  operations;  (x) loss of  customers;(xi)
adverse  determinations in connection with pending or future litigation or other
material  claims and judgments  against the Company;  (xii) inability to achieve
future sales; and (xiii) the  unavailability of funds for capital  expenditures.
Many of such factors are beyond the control of the Company.  Please refer to the
Company's  SEC Form 10-K for its  fiscal  year  ended  December  31,  1997,  for
additional cautionary statements.


<PAGE>


                                     PART II


Item 1.  Legal Proceedings - None.
Item 2.  Changes in Securities and Use of Proceeds - None.
Item 3.  Defaults upon Senior Securities - None.
Item 4.  Submission of Matters to a Vote of Security Holders

Matters  submitted at the annual meeting of shareholders held June 4, 1998, were
to  obtain  the vote of  shareholders  to elect  Dean G.  Constantine,  David J.
McNally,  Phillip L. McStotts,  Bradly A. Oldroyd and Darla R. Gill as directors
of the  Company  to serve  one-,  two-,  or  three-year  terms  and  ratify  the
appointment by the Board of Directors,  for Ernst & Young, LLP, certified public
accountants,  as the independent  auditors for the year ended December 31, 1998.
Both of these matters were approved by the shareholders. For further details see
ZEVEX International, Inc. proxy statement filed with the Securities and Exchange
Commission on or about April 29, 1998.

Item 5.  Other Information

On July 28, 1998, ZEVEX International,  Inc.'s. wholly-owned subsidiary,  ZEVEX,
Inc.  signed an agreement to acquire the product  rights to the enteral  feeding
pumps, delivery sets and feeding tubes of Minneapolis, Minnesota-based Nutrition
Medical  Inc..  Enteral pumps deliver  nutrition to patients  requiring  feeding
through the intestines or stomach. Total sales of these products for the past 12
months ending June 30, 1998 were approximately $2 million. Consideration for the
transaction will be approximately  $1.42 million,  comprised of cash of $500,000
and 115,000  shares of ZEVEX  International  common stock,  currently  valued at
$920,000.

The acquisition is subject to approval by Nutrition Medical Inc. shareholders, 
which is expected in the fourth quarter 1998.  Effective immediately ZEVEX has
entered into an exclusive marketing agreement for these product lines.  The
marketing agreement will be in effect until the completion of the acquisition.

Item 6. Exhibits and Reports on Form 8-K - None.



-------------------------------------------------------------------------------

                                   SIGNATURES
-------------------------------------------------------------------------------

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the  Registrant  has duly  caused  this report to be signed on its behalf by the
undersigned thereunto duly authorized.


ZEVEX INTERNATIONAL, INC.


Dated:  August 6, 1998
                       By /s/ Dean G. Constantine
                       Dean G. Constantine, President


                       By /s/ Phillip L. McStotts
                       Phillip L. McStotts, Secretary
                       (Principal Financial Officer)